The Effects of Celecoxib or Naproxen on Blood Pressure in Pediatric Patients with Juvenile Idiopathic Arthritis

Falkner, Bonita; Berger, Manuela; Brown, P. Bhadra; Iorga, Dinu; Nickeson, Robert W.

doi:10.4137/cmped.s20720

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Falkner et al assessed a comparable safety profile for celecoxib (50 or 100 mg twice daily) in comparison with naproxen (7.5 mg/kg twice daily) in JIA patients aged 2–17 years [ 137 ]. Even though indomethacin is a potent anti-inflammatory and antipyretic agent in children with JIA, it is less frequently used [ 10 , 111 ].…”

Section: Efficacy Of Nsaidsmentioning

confidence: 99%

Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years

Ziesenitz

Welzel²,

Dyk³

et al. 2022

Pediatr Drugs

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with childspecific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.

show abstract

Section: Efficacy Of Nsaidsmentioning

confidence: 99%